Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model

Journal of Drug Targeting

Volumn 14, Issue 4, 2006, Pages 233-241

  Khan, Masood A ^a,b   Faisal, S M ^a   Mohammad, Owais ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Immunomodulator; Liposomes; Nystatin; Tuftsin

Indexed keywords

CREATININE; LIPOSOME; NYSTATIN; TUFTSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD SAMPLING; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; ERYTHROCYTE COUNT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPOTENTIATION; IN VITRO STUDY; IN VIVO STUDY; LUNG ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; LIPOSOMES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; NYSTATIN; TREATMENT OUTCOME; TUFTSIN;

EID: 33745273874     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600720384     Document Type: Article

References (25)

1. Alvarez, ME and Sanchez-Souza, A and Baquero, F. (1998) A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis Rev Esp Quimioter, 11, pp. 295-315.
2. Craig, WA. (1998) Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin Infect Dis, 26, pp. 1-12.
3. Georgeopapadakou, NH and Walsh, TJ. (1996) Antifungal agents: Chemotherapeutic targets and immunologic strategies Antimicrob Agents Chemother, 40, pp. 279-291.
4. Groll, AH and Gonzalez, CE and Giri, N and Kligys, K and Love, W and Peter, J and Feuerstein, E and Bacher, J and Piscitelli, SC and Walsh, TJ. (1998) Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative target for antifungal drug development Adv Pharmacol, 44, pp. 343-500.
5. Hossain, MA and Maesaki, S and Razzaque, MS and Tomono, K and Taguchi, T and Kohno, S. (2000) Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating nystatin J Antimicrob Chemother, 46(2), pp. 263-268.
6. Khan, MA and Faisal, SM and Haque, W and Owais, M. (2002) Immunomodulator tuftsin augments antifungal activity of amphotericin B against experimental murine Candidiasis J Drug Target, 10(3), pp. 185-192.
7. Khan, MA and Nasti, TH and Khanam, S and Mallick, AI and Ahmad, F and Haq, W and Ahmad, N and Owais, M. (2004) Coadministartion of immunomodulator tuftsin and liposomised-nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice FEMS Immunol Med Microbiol, 41, pp. 249-258.
8. Lee, JW and Navarro, E and Francis, P and Mc Manus, E and Schaufele, R and Bacher, J and Pizzo, PA and Walsh, TJ. (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of nystatin (Ambisome) in rabbits Antimicrob Agents Chemother, 38, pp. 713-718.
9. Legrand, P and Romero, EA and Cohen, BE and Bolard, J. (1992) Effects of aggregation and solvent on the toxicity of Nystatin on human erythrocytes Antimicrob Agents Chemother, 36(11), pp. 2518-2522.
10. Lupetti, A and Danesi, R and Campa, M and Tacca, MD and Kelly, S. (2002) Molecular basis of resistance to azole antifungals Trends Mol Med, 8(2), pp. 76-81.
11. Mehta, RT and Hopfer, RL and McQueen, T and Juliano, RL and Lopez-Berestein, G. (1987) Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections Antimicrob Agents Chemother, 31, pp. 1901-1913.
12. National Committee for Clinical Laboratory Standards.(1997) Method for broth dilution antifungal susceptibility testing for yeasts: Approved standard M 27-A. In. Wayne, Pa: National Committee for Clinical Laboratory Standards.
13. Ng, AWK and Wasan, KM. (2003) Development of liposomal polyene antibiotics: An historical perspective J Pharm Pharm Sci, 6(1), pp. 67-83.
14. Pace, HR and Schantz, SI. (1956) Nystatin (Mycostatin) in the treatment of monilial and nonmonilial vaginitis JAMA, 162, pp. 268-271.
15. Perkins, WR and Minchey, SR and Boni, LT and Swenson, CE and Popescu, MC and Pasternack, RF and Janoff, AS. (1992) Nystatin phospholipid interactions responsible for reduced mammalian cell toxicity Biochim Biophys Acta, 1107, pp. 271-281.
16. Sanglard, D and Ischer, F and Calabrese, D and Micheli, M and Bille, J. (1998) Multiple resistance mechanisms to azole antifungals in yeast clinical isolates Drug Resist Updat, 1, pp. 255-265.
17. Siemion, IZ and Kluczyk, A. (1999) Tuftsin: On the 30-year anniversary of Victor Najjar's discovery Peptides, 20, pp. 645-674.
18. Singhal, A and Bali, A and Jain, RK and Gupta, CM. (1984) Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers FEBS Lett, 178, pp. 109-113.
19. Singleton, T and Gray, WS and Brown, ML. (1965) A method for adsorbent fractionation of cottonseed oil for experimental intravenous fat emulsions J Am Oil Chem Soc, 42, pp.53- 56.
20. Sterling, TR and Merz, WG. (1998) Resistance to nystatin: Emerging clinical and microbiological patterns Drug Resist Updat, 1, pp. 161-165.
21. Trevisani, F and Castelli, E and Foschi, FG and Parazza, M and Loggi, E and Bertelli, M and Melotti, C and Domenicali, M and Zoli, G and Bernardi, M. (2002) Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical outcome Gut, 50, pp. 707-712.
22. Van Etten, EWM and Otte-Lambillion, M and Van Vianen, W and ten Kate, MT and Bakker-Woundenberg, IAJM. (1995) Biodistribution of liposomal nystatin deoxycholate (fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans J Antimicrob Chemother, 35, pp. 509-519.
23. Wallace, TL and Paetznick, B and Cossum, PA and Lopez-Berestain, G and Rex, JH and Anaissie, E. (1997) Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice Antimicrob Agents Chemother, 41, pp. 2238-2243.
24. Wasan, KM and Mortan, RE and Rosenblum, MG and Lopez-Berestein, G. (1994) Decreased toxicity of liposomal nystatin due to association of nystatin with high density lipoproteins: Role of lipid transfer protein J Pharm Sci, 83, pp. 1006-1010.
25. Wey, SB and Mori, M and Pfaller, MA and Woolson, RF and Wenzel, RP. (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay Arch Intern Med, 148, pp. 2642-2645.